Partner, Morrison & Foester
Michael O’Donnell is a partner in the firm’s Palo Alto office, specializing in corporate and securities law. He has more than 30 years of experience providing general corporate representation to biopharmaceutical and other life sciences companies. He offers particular expertise in venture capital financings, public offerings, mergers and acquisitions, strategic alliances, technology licensing, and corporate spin-out transactions. He represents numerous public and private biopharmaceutical, medical device, diagnostic, and instrumentation companies.
Michael was the founding attorney and lead attorney on the initial public offerings for companies such as Illumina, Pain Therapeutics, Cytokinetics, NeurogesX, Neurocrine Biosciences, Sequana Therapeutics, Ciphergen Biosystems, Argonaut Technologies, and Microcide Pharmaceuticals.
He also has extensive experience with negotiating strategic alliances, representing clients in major collaborations with GSK, Amgen, Schering-Plough, J&J, Daiichi, Astellas, Valeant, and King Pharmaceuticals and most recently with Pfizer, Baxter, Eisai and Dainippon Sumitomo Pharma Co., Ltd.
Michael was also the lead attorney responsible for negotiating a number of notable biopharmaceutical spin-outs, including Onyx Pharmaceuticals (Chiron-Cetus), Tularik (Genentech), X-Ceptor (Ligand Pharmaceuticals), Metabasis (Gensia Sicor), and Iconix (Microcide Pharmaceuticals) and as well on the reverse merger of Transcept Pharmaceuticals with Novacea, creating a new publicly traded entity.
Harvard Law School, (J.D., Cum Laude, 1983)
Bucknell University (B.A., Summa Cum Laude, Phi Beta Kappa, 1980)
Legal 500 Us 2015
Recognized In The Areas Of Healthcare And Venture Capital And Emerging Companies